top of page

NCT-0563-3654

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecanand Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy


This research study is looking at a new treatment for triple-negative breast cancer. The new treatment being studied in this trial is a combination of two drugs: sacituzumab govitecan and pembrolizumab. Sacituzumab govitecan is a type of drug called an antibody-drug conjugate (ADC). ADCs are made up of an antibody that is linked to a chemotherapy drug. The antibody helps the ADC target cancer cells, and the chemotherapy drug kills the cancer cells. Pembrolizumab is a type of drug called a checkpoint inhibitor. Checkpoint inhibitors help the immune system recognize and attack cancer cells. The goal of the trial is to see if the new treatment is more effective and safer than the standard treatment at improving survival rates and reducing the risk of cancer recurrence.


Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.


For more information about the trial, click the link below:

NCT-0563-3654

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CAR

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatoce

Comentarios


bottom of page